Drugs / BLU-701
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05153408 | Jan → Dec 2022 | adenocarcinoma, bronchogenic carcinoma, non-small cell lung carcinoma | Blueprint Medicines Corporation | Terminated | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-11-09 | Zai Lab (Shanghai) Co., Ltd. | Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China zailaboratory.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BLU-701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05153408 ↗ |
| Action | Inhibit | “Highly Selective EGFR Inhibitor” NCT05153408 ↗ |
| Route | Oral | “BLU-701 for oral administration” NCT05153408 ↗ |
| Target | EGFR | “Highly Selective EGFR Inhibitor” NCT05153408 ↗ |